Quick Answer
Armata Pharmaceuticals, Inc. reported Net Income of -$173.80 million for fiscal year 2025.
Armata Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$173.80M -818.8% |
-$18.92M +72.6% |
-$69.05M -87.0% |
-$36.92M -59.4% |
-$23.16M -4.4% |
-$22.18M -13.9% |
| Diluted EPS | -$4.80 -439.3% |
-$0.89 +53.4% |
-$1.91 -76.9% |
-$1.08 -12.5% |
-$0.96 +28.9% |
-$1.35 +47.1% |
| Total Assets | $76.88M -11.1% |
$86.44M -12.1% |
$98.36M +2.6% |
$95.83M +37.4% |
$69.77M +76.6% |
$39.52M +55.3% |
| Cash and Equivalents | $8.69M -6.5% |
$9.29M -31.3% |
$13.52M -8.9% |
$14.85M +44.4% |
$10.29M +6.6% |
$9.65M +59.9% |
| Stockholders Equity | -$218.60M -355.2% |
-$48.02M -49.8% |
-$32.06M -188.9% |
$36.08M +42.1% |
$25.40M +34.7% |
$18.86M +29.2% |
| R&D Expense | — | — | — | — | — | — |
| Operating Income | -$36.63M +13.7% |
-$42.44M -3.8% |
-$40.89M -10.7% |
-$36.95M -55.1% |
-$23.82M -10.4% |
-$21.59M -9.3% |
| Shares Outstanding | 36.43M +0.7% |
36.18M +0.2% |
36.12M -0.1% |
36.14M +33.3% |
27.11M +45.1% |
18.69M +88.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$26.68M | -386.7% | -63.7% |
| Diluted EPS | September 30, 2025 | -$0.74 | -393.3% | -64.4% |
| Total Assets | September 30, 2025 | $89.52M | -8.9% | +10.8% |
| Cash and Equivalents | September 30, 2025 | $14.76M | -13.9% | +240.9% |
| Stockholders Equity | September 30, 2025 | -$95.59M | -87.5% | -37.5% |
| R&D Expense | March 31, 2019 | $1.49M | +2.0% | +313.9% |
| Operating Income | September 30, 2025 | -$7.78M | +20.3% | -13.6% |
| Shares Outstanding | September 30, 2025 | 3.62M | -90.0% | -90.0% |
- Armata Pharmaceuticals, Inc. reported Net Income of -$173.80 million for fiscal year 2025.
- Armata Pharmaceuticals, Inc. showed a decrease of -818.8% in Net Income compared to the prior fiscal year.
- Armata Pharmaceuticals, Inc. reported Diluted EPS of $4.80 per share (loss) for fiscal year 2025.
- Armata Pharmaceuticals, Inc. showed a decrease of -439.3% in Diluted EPS compared to the prior fiscal year.
- Armata Pharmaceuticals, Inc. reported Total Assets of $76.88 million for fiscal year 2025.
- Armata Pharmaceuticals, Inc. showed a decrease of -11.1% in Total Assets compared to the prior fiscal year.
- Armata Pharmaceuticals, Inc. reported Cash and Equivalents of $8.69 million for fiscal year 2025.
- Armata Pharmaceuticals, Inc. showed a decrease of -6.5% in Cash and Equivalents compared to the prior fiscal year.
- Armata Pharmaceuticals, Inc. reported Stockholders Equity of -$218.60 million for fiscal year 2025.
- Armata Pharmaceuticals, Inc. showed a decrease of -355.2% in Stockholders Equity compared to the prior fiscal year.
- Armata Pharmaceuticals, Inc. reported R&D Expense of $9.82 million for fiscal year 2019.
- Armata Pharmaceuticals, Inc. showed an increase of +17.3% in R&D Expense compared to the prior fiscal year.
- Armata Pharmaceuticals, Inc. reported Operating Income of -$36.63 million for fiscal year 2025.
- Armata Pharmaceuticals, Inc. showed an increase of +13.7% in Operating Income compared to the prior fiscal year.
- Armata Pharmaceuticals, Inc. reported Shares Outstanding of 36.43 million shares for fiscal year 2025.
- Armata Pharmaceuticals, Inc. showed an increase of +0.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: